+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter phase II trial of first-line irinotecan and gemcitabine in patients with unresectable pancreatic cancer



Multicenter phase II trial of first-line irinotecan and gemcitabine in patients with unresectable pancreatic cancer



European Journal of Cancer 37(Supplement 6): S313




(PDF emailed within 1 workday: $29.90)

Accession: 035349871

Download citation: RISBibTeXText


Related references

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer 95(5): 587-592, 2006

Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer: A multicenter phase II trial. Journal of Clinical Oncology 24(18_suppl): 4124-4124, 2016

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology 18(4): 745-751, 2007

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology 16(10): 1639-1645, 2005

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645. Annals of Oncology 17(3): 535-535, 2006

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer ChemoTherapy and Pharmacology 65(3): 527-536, 2010

Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. European Journal of Cancer 54: 96-103, 2016

First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer ChemoTherapy and Pharmacology 68(5): 1173-1178, 2011

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. Journal of Clinical Gastroenterology 44(4): 286-288, 2010

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Journal of Clinical Oncology 23(16_suppl): Lba4009-Lba4009, 2016

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology 24(7): 1792-1801, 2013

Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology 70(2): 106-114, 2006

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology 35(29): 3330-3337, 2017

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer ChemoTherapy and Pharmacology 60(2): 295-303, 2006

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Annals of Oncology 14(3): 388-394, 2003